Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT06264921 Recruiting - Ovarian Cancer Clinical Trials

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Start date: February 23, 2024
Phase: Phase 1
Study type: Interventional

The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of NKT3447 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and the preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected in Dose Escalation and to determine the preliminary recommended phase 2 dose (RP2D).

NCT ID: NCT06259552 Recruiting - Solid Tumor Clinical Trials

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

SPX-303
Start date: March 20, 2024
Phase: Phase 1
Study type: Interventional

Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.

NCT ID: NCT06258330 Recruiting - Solid Tumor Clinical Trials

Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors

Start date: June 22, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1, first-in-human study to assess the safety and tolerability of AM003 in patients with locally advanced and metastatic solid tumors

NCT ID: NCT06249256 Recruiting - Solid Tumor Clinical Trials

An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells

Start date: June 1, 2023
Phase: Early Phase 1
Study type: Interventional

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of fast autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies in patients with solid tumors.

NCT ID: NCT06248697 Recruiting - Solid Tumor Clinical Trials

Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors

Start date: January 1, 2023
Phase: Early Phase 1
Study type: Interventional

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 and CTLA-4 nanobodies (αPD1/CTLA-4-MSLN-CAR T cells) in patients with solid tumors.

NCT ID: NCT06245330 Recruiting - Pancreatic Cancer Clinical Trials

A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors

Start date: July 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of AST-001 administered as a single agent.

NCT ID: NCT06245018 Not yet recruiting - Solid Tumor Clinical Trials

A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

This trial is to investigate the safety, efficacy of iNK in subjects with solid tumor. It is a dose escalation and extension trial.

NCT ID: NCT06241898 Recruiting - Solid Tumor Clinical Trials

A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors

Start date: October 1, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to test in patients with local advanced/metastatic solid tumors. the main questions it aims to answer are: - to assess the safety and tolerability of BB-1709. - to determine the maximum tolerated dose(MTD) and/or the PR2D of BB-1709

NCT ID: NCT06239623 Recruiting - Melanoma Clinical Trials

ERK Inhibitor JSI-1187 in Advanced Solid Tumors

Start date: April 2, 2022
Phase: Phase 1
Study type: Interventional

JSI-1187-101 phase 1 study

NCT ID: NCT06239298 Not yet recruiting - Solid Tumor Clinical Trials

A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

Start date: May 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Multi-center, Open-labe, Phase I/II Study to evaluate the safety and tolerability of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor.